ReviewFrontiers in immunology2026
Accelerated immunosenescence in SLE: current evidence and clinical translation.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with systemic lupus erythematosus (SLE) often develop age-related adverse outcomes at a young age, raising the possibility that immune-aging processes may interact with chronic immune activation, treatment exposure, and accumulated damage in shaping long-term disease burden. Although immune-age acceleration has also been reported in rheumatoid arthritis and chronic viral infections (e.g., HIV/CMV), SLE is particularly well suited as a human model of inflammation-driven immune aging because of its typical onset in young women and the convergence of aging signatures across clinical, cellular, and molecular levels. Main body: This review synthesizes evidence for accelerated immunosenescence in SLE across systemic manifestations, immune cell remodeling, and molecular senescence markers. Clinically, SLE is linked to premature cardiovascular disease, frailty, cognitive impairment, severe infections, and reduced vaccine responsiveness. Immunologically, senescent-like immune subsets (including terminally differentiated T cells, age-associated/double-negative B cells, dysfunctional NK cells, and senescence-like myeloid cells) expand prematurely. Molecular features include inflammaging-like cytokine patterns, telomere attrition, and epigenetic age acceleration. We also discuss a translational framework for quantifying immunosenescence using immunophenotyping, telomere/epigenetic clocks, and composite immune clocks, with potential applications in risk stratification, treatment decisions, and monitoring immune-reprogramming strategies. Conclusions: Accelerated immunosenescence provides a biologically plausible and clinically relevant framework for understanding SLE heterogeneity across systemic, cellular, and molecular levels. However, immune-aging measures should currently be regarded as candidate research biomarkers rather than validated clinical decision tools. Prospective SLE-specific studies are needed to establish their predictive value, disease specificity, and clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.